Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.
about
68Ga-Based radiopharmaceuticals: production and application relationshipApplication of cross-species PET imaging to assess neurotransmitter release in brainDevelopment of positron emission tomography β-amyloid plaque imaging agentsThe development, past achievements, and future directions of brain PETImaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in HypoxiaModeling of PET data in CNS drug discovery and development.Synthesis of [11C]/(13C)amines via carbonylation followed by reductive amination.Application of palladium-mediated (18)F-fluorination to PET radiotracer development: overcoming hurdles to translation.A computerized infusion pump for control of tissue tracer concentration during positron emission tomography in vivo pharmacokinetic/pharmacodynamic measurements.Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.Positron emission tomography molecular imaging for drug development.Unveiling molecular events in the brain by noninvasive imaging.Imaging and cancer: a review.PET tracers for serotonin receptors and their applicationsDevelopment of radiotracers for oncology--the interface with pharmacologyDistribution of intravenously administered acetylcholinesterase inhibitor and acetylcholinesterase activity in the adrenal gland: 11C-donepezil PET study in the normal ratMedical imaging in new drug clinical development.In Vivo Tissue Pharmacokinetics of Carbon-11-Labeled Clozapine in Healthy Volunteers: A Positron Emission Tomography Study.Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.Compact microfluidic device for rapid concentration of PET tracersPositron emission tomography and single-photon emission computed tomography in central nervous system drug development.Molecular theranostics: a primer for the imaging professionalHigh-efficiency γ-ray flash generation via multiple-laser scattering in ponderomotive potential well.Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates.Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380.Functional PET imaging in cancer drug development.In vivo imaging of pyrrole-imidazole polyamides with positron emission tomography.Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrierInteraction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomographyApproaches using molecular imaging technology -- use of PET in clinical microdose studies.Intestinal permeability and its relevance for absorption and elimination.Whatever happened to Pittsburgh Compound-A?The role of clinical imaging in oncological drug development.Effects of anesthesia and species on the uptake or binding of radioligands in vivo in the Göttingen minipig.A review of imaging agent development.Prospective of ⁶⁸Ga-radiopharmaceutical development.[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans.Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging.
P2860
Q26801794-3315B94D-CEC3-4695-93B1-4747A0032FBFQ26865012-2A4AA33F-74D4-4C06-8054-E07E3D7915FFQ27012742-4905A64F-76F8-4E3D-9047-00A4BA2E81C2Q27026331-45F81444-8DD4-4037-9E21-8F939A1489EFQ28553813-08FE2812-CFA1-4B23-8FE5-C592A523BFF1Q30623699-6F362E56-9DF9-4119-A8D2-6938E18FC332Q31065994-D5387FDC-DC05-4922-8BF4-C84615033C48Q31114482-02883567-5624-4B06-8A15-415678DDA2C7Q33338968-6E5E17E0-F78D-493C-B49C-74AEA379AD86Q33696408-C0106DBC-81BE-44B7-9679-355E6DFA2F0CQ33991881-02867FB7-24E5-4F12-9F95-F40F19F8DC22Q34046040-2BD61870-571E-4B08-B124-3C8087692526Q34977050-06F986B5-CEC6-4C48-87E6-DB98B88E6A12Q35090637-78E1B8A8-02A1-417B-A81D-28277D7451C1Q35195500-90E1B7B7-D9A1-46A4-8AFA-B74EE0DB0790Q35254862-C3C954B1-D2C8-4B16-BD00-745665B31F4DQ35667744-3598AC1B-0E8B-4974-AA4E-71466E68642BQ35676051-DADEF654-6EF3-49B9-A342-FB31356C17ECQ35719906-DCEEE649-9D07-4406-A67A-EDE94D0280C3Q35735512-AD5CDA71-997C-4B1E-9BA2-C1B0063580C2Q36129732-0B376B96-ECCF-4D5D-B743-FE17FFAC6A9DQ36251545-BC88B279-2501-41B8-9583-0C2C83080232Q36283166-11B8C9E3-A02B-409A-8A1C-D90EB89F6818Q36287874-D64CD50B-0EAD-4733-8BA6-220B436B691FQ36618309-7E5A817B-78A7-4724-9618-C6FAF29AFCD9Q36662874-F62D8C57-8F2A-4592-BF39-122C1592ADF9Q36768305-097CC542-AB2B-4FCA-B940-02335F853F3CQ36861667-FE2935BE-2998-4C5A-83E9-9AA3CB1806BCQ36949089-F71112E9-D110-418D-BF64-3D7DF05C7D7BQ36949407-002B511B-4A14-4F22-82D2-34F2DD5ACA28Q36953094-8352171A-EB18-494F-9614-F0572864A063Q36985043-7349C509-63B6-42DE-8868-6CBA7F8A190AQ37111564-3C1028C2-7439-4AF1-BB4D-260B9FA2E541Q37187098-9BF20D98-154E-4250-9926-4DDFFA849F42Q37191041-252D7926-307F-407D-B8C7-B0A6BEAB5466Q37214528-8D98CCBD-3914-4266-A618-B28EFA4E93B9Q37435222-AB0AA3AC-5C36-4AAF-B39B-4C2C7F33B741Q37568411-BE7C4638-33E6-4B0A-81D9-836B2962EAF5Q37701128-2E28901F-D041-4243-BDA0-D9EC95748AF6Q37770188-9E7C7889-328D-49C4-B891-C4A96A618D47
P2860
Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Positron emission tomography m ...... rly clinical drug development.
@ast
Positron emission tomography m ...... rly clinical drug development.
@en
type
label
Positron emission tomography m ...... rly clinical drug development.
@ast
Positron emission tomography m ...... rly clinical drug development.
@en
prefLabel
Positron emission tomography m ...... rly clinical drug development.
@ast
Positron emission tomography m ...... rly clinical drug development.
@en
P1476
Positron emission tomography m ...... rly clinical drug development.
@en
P2093
Anders Grahnén
Mats Bergström
P2888
P304
P356
10.1007/S00228-003-0643-X
P577
2003-08-22T00:00:00Z